Image taken from Roche website http://www.roche.com/research_and_development/drawn_to_science/target_identification.htm

Rethinking Drug Discovery & Research Models in India

Drug discovery is a high risk, high return business. Despite the intrinsic risks, pharma companies continue to invest heavily in R&D to improve the quality of life of patients in needs of treatment. While capital is important in R&D outcomes, innovation-based organisations need to understand the best model to adopt to speed up the process in bringing discoveries to useful commercial …

IBM Watson to Boost Pharma R&D and Reduce Costs

  IBM Watson is taking research to levels of speed unreachable by humans IBM announced last week the next step in Watson Discovery Advisor’s cognitive computing capabilities. Now available as a cloud service, it is already showing its potential to help research teams in all sectors accelerate research and discovery processes, by quickly analysing data in millions of scientific papers …

Increasing innovation and decreasing costs in R&D through advantages of the Indian market, by Mr Satish Jindal

Speaking on the above topic is Mr Satish Jindal, Vice President & Managing Director Biocon-BMS Research Center, India. He will be presenting at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012. A short background on Biocon-BMS Research Center: BBRC is a BMS R&D center for Drug Discovery and Development in …